AU2007244927B2 - Predicting mortality and detecting severe disease - Google Patents

Predicting mortality and detecting severe disease Download PDF

Info

Publication number
AU2007244927B2
AU2007244927B2 AU2007244927A AU2007244927A AU2007244927B2 AU 2007244927 B2 AU2007244927 B2 AU 2007244927B2 AU 2007244927 A AU2007244927 A AU 2007244927A AU 2007244927 A AU2007244927 A AU 2007244927A AU 2007244927 B2 AU2007244927 B2 AU 2007244927B2
Authority
AU
Australia
Prior art keywords
subject
level
soluble
risk
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007244927A
Other languages
English (en)
Other versions
AU2007244927A1 (en
Inventor
Sven Jacobson
James V. Snider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Critical Care Diagnostics Inc
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of AU2007244927A1 publication Critical patent/AU2007244927A1/en
Application granted granted Critical
Publication of AU2007244927B2 publication Critical patent/AU2007244927B2/en
Priority to AU2012202069A priority Critical patent/AU2012202069B2/en
Priority to AU2016200419A priority patent/AU2016200419B2/en
Priority to AU2018202815A priority patent/AU2018202815A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
AU2007244927A 2006-04-24 2007-04-24 Predicting mortality and detecting severe disease Ceased AU2007244927B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2012202069A AU2012202069B2 (en) 2006-04-24 2012-04-11 Predicting mortality and detecting severe disease
AU2016200419A AU2016200419B2 (en) 2006-04-24 2016-01-25 Predicting mortality and detecting severe disease
AU2018202815A AU2018202815A1 (en) 2006-04-24 2018-04-23 Predicting mortality and detecting severe disease

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79435406P 2006-04-24 2006-04-24
US60/794,354 2006-04-24
US80036206P 2006-05-15 2006-05-15
US60/800,362 2006-05-15
US90460807P 2007-03-02 2007-03-02
US60/904,608 2007-03-02
PCT/US2007/067333 WO2007127749A2 (en) 2006-04-24 2007-04-24 Predicting mortality and detecting severe disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202069A Division AU2012202069B2 (en) 2006-04-24 2012-04-11 Predicting mortality and detecting severe disease

Publications (2)

Publication Number Publication Date
AU2007244927A1 AU2007244927A1 (en) 2007-11-08
AU2007244927B2 true AU2007244927B2 (en) 2012-01-12

Family

ID=38656334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007244927A Ceased AU2007244927B2 (en) 2006-04-24 2007-04-24 Predicting mortality and detecting severe disease

Country Status (12)

Country Link
US (7) US7998683B2 (zh)
EP (5) EP2010912B1 (zh)
JP (4) JP5383480B2 (zh)
AT (2) ATE527544T1 (zh)
AU (1) AU2007244927B2 (zh)
CA (1) CA2650201C (zh)
DE (1) DE602007008224D1 (zh)
DK (3) DK2848938T3 (zh)
ES (4) ES2646142T3 (zh)
HK (3) HK1164443A1 (zh)
PL (2) PL2386860T4 (zh)
WO (1) WO2007127749A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK1532269T3 (da) 2002-05-09 2012-03-12 Brigham & Womens Hospital 1L1RL-1 som markør for kardiovaskulær sygdom
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
EP2010912B1 (en) 2006-04-24 2010-08-04 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
JP5377289B2 (ja) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
JP2009538386A (ja) * 2006-05-25 2009-11-05 モメンタ ファーマシューティカルズ インコーポレイテッド 低分子量ヘパリン組成物およびその使用
US11389080B2 (en) 2007-11-28 2022-07-19 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
WO2009100907A1 (en) * 2008-02-14 2009-08-20 Dianeering Diagnostics Engineering And Research Gmbh Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers
WO2009105522A1 (en) * 2008-02-20 2009-08-27 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
PT2827152T (pt) * 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
EP2141499A1 (en) 2008-07-02 2010-01-06 Apoptec AG COPD diagnosis
US9883799B2 (en) * 2008-10-16 2018-02-06 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US20100099958A1 (en) * 2008-10-16 2010-04-22 Fresenius Medical Care Holdings Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US10064580B2 (en) 2008-11-07 2018-09-04 Intervet Inc. System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis
JP2012063139A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による膵臓がんの診断方法
JP2012063140A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による肺がんの診断方法
US20120322760A1 (en) * 2009-09-23 2012-12-20 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
WO2011060361A1 (en) * 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
JP6092092B2 (ja) * 2010-03-26 2017-03-08 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 腎機能障害、糸球体濾過速度、呼吸困難、急性心不全、左心室肥大、心線維症、子癇前症、妊娠関連蛋白尿のバイオマーカーとしてのｌｔｂｐ２
CA2795200C (en) 2010-04-09 2020-01-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
JP2011232164A (ja) * 2010-04-27 2011-11-17 Keio Gijuku 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
US20110295613A1 (en) * 2010-05-28 2011-12-01 Martin Coyne Inpatient utilization management system and method
US20130302841A1 (en) * 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
WO2012075222A2 (en) 2010-12-02 2012-06-07 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AU2012284039B2 (en) 2011-07-18 2017-03-30 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JP6302896B2 (ja) * 2012-05-18 2018-03-28 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
WO2014028875A1 (en) * 2012-08-16 2014-02-20 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
SG10201608854TA (en) 2012-08-21 2016-12-29 Critical Care Diagnostics Inc Multimarker risk stratification
BR122022005675B1 (pt) 2013-02-06 2023-05-02 Geissler Companies, Llc Métodos para determinar a eficácia de uma droga
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2016066698A1 (en) 2014-10-29 2016-05-06 Roche Diagnostics Gmbh Biomarkers for risk prediction of mortality
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN106952043B (zh) * 2017-03-23 2021-04-13 国家电网公司客户服务中心 一种计划停电敏感度评估方法和装置
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
CR20220461A (es) 2020-03-13 2022-10-21 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja) 1989-06-02 1995-07-19 内橋エステック株式会社 温度ヒューズ
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CA2263832A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
JP2001513641A (ja) 1997-02-28 2001-09-04 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｔ１／ｓｔ２−レセプターリガンド▲ｉｉｉ▼
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
AU7590198A (en) * 1997-06-10 1998-12-30 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
CN1161609C (zh) 1997-09-11 2004-08-11 盐野义制药株式会社 哺乳类γ－BNP衍生物特异的免疫测定方法及其试剂盒
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
AU2055300A (en) 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
BR0107157A (pt) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnose e tratamento de condições cardiovasculares
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
DK1532269T3 (da) * 2002-05-09 2012-03-12 Brigham & Womens Hospital 1L1RL-1 som markør for kardiovaskulær sygdom
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
AU2003239544A1 (en) * 2002-05-24 2003-12-12 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20070042978A1 (en) * 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) * 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005042795A2 (en) 2003-10-31 2005-05-12 Queststar Medical, Inc. Plasma polymerization of atomically modified surfaces
WO2005056837A2 (en) * 2003-11-26 2005-06-23 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) * 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1833766A1 (en) 2004-12-17 2007-09-19 Clearwater Systems Corp. Method and apparatus for treating fluids
DE602006003411D1 (de) 2005-01-24 2008-12-11 Roche Diagnostics Gmbh Verwendung von Herzhormonen zur Diagnose des Kardiovaskuläre Risikos als folge einer Verabreichung von Entzündungshemmern
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) * 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
EP2010912B1 (en) * 2006-04-24 2010-08-04 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
JP5377289B2 (ja) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2158330A2 (en) 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
EP2347266B9 (en) 2008-11-11 2014-02-12 B.R.A.H.M.S GmbH Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm
WO2011060361A1 (en) 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
CA2795200C (en) 2010-04-09 2020-01-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
US20130302841A1 (en) 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AU2012284039B2 (en) 2011-07-18 2017-03-30 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
JP6302896B2 (ja) 2012-05-18 2018-03-28 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
WO2014028875A1 (en) 2012-08-16 2014-02-20 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
SG10201608854TA (en) 2012-08-21 2016-12-29 Critical Care Diagnostics Inc Multimarker risk stratification
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHIMPO, M. et al., Circulation, 2004, Vol. 109, pages 2186-2190 *
TSUCHIYA, T. et al., Blood, 2004, Vol. 103, No. 1, pages 236-241 *
WEINBERG, E. O. et al., Circulation, 2003, Vol. 107, pages 721-726 *

Also Published As

Publication number Publication date
US9057733B2 (en) 2015-06-16
ES2351623T3 (es) 2011-02-08
JP2012181200A (ja) 2012-09-20
JP5383480B2 (ja) 2014-01-08
HK1248311B (zh) 2020-03-20
EP2386860A2 (en) 2011-11-16
DK2241888T3 (da) 2012-01-30
CA2650201C (en) 2020-10-20
JP5806165B2 (ja) 2015-11-10
PL2848938T3 (pl) 2018-02-28
PL2386860T4 (pl) 2015-09-30
US20120040381A1 (en) 2012-02-16
DE602007008224D1 (de) 2010-09-16
HK1208724A1 (zh) 2016-03-11
DK2848938T3 (da) 2017-11-13
EP2241888B1 (en) 2011-10-05
EP2010912B1 (en) 2010-08-04
EP2848938A1 (en) 2015-03-18
ATE476657T1 (de) 2010-08-15
JP2016001193A (ja) 2016-01-07
PL2386860T3 (pl) 2015-08-31
WO2007127749A3 (en) 2008-03-20
EP2010912A4 (en) 2009-06-10
ES2529618T3 (es) 2015-02-23
EP2010912A2 (en) 2009-01-07
EP2386860B1 (en) 2014-11-05
CA2650201A1 (en) 2007-11-08
HK1164443A1 (zh) 2012-09-21
EP2386860A3 (en) 2012-02-22
US20140045200A1 (en) 2014-02-13
US10067146B2 (en) 2018-09-04
US9568481B2 (en) 2017-02-14
US20170131294A1 (en) 2017-05-11
ATE527544T1 (de) 2011-10-15
ES2378314T3 (es) 2012-04-11
US11016103B2 (en) 2021-05-25
EP2241888A2 (en) 2010-10-20
ES2646142T3 (es) 2017-12-12
EP3255432A1 (en) 2017-12-13
JP2009534691A (ja) 2009-09-24
EP2241888A3 (en) 2010-11-03
US20070248981A1 (en) 2007-10-25
AU2007244927A1 (en) 2007-11-08
US20110262941A1 (en) 2011-10-27
JP6214604B2 (ja) 2017-10-18
US20190041403A1 (en) 2019-02-07
US7998683B2 (en) 2011-08-16
US8617825B2 (en) 2013-12-31
US20210255200A1 (en) 2021-08-19
JP2017215347A (ja) 2017-12-07
EP3255432B1 (en) 2019-01-23
DK2386860T3 (en) 2015-02-09
WO2007127749A2 (en) 2007-11-08
EP2848938B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
US20210255200A1 (en) Predicting mortality and detecting severe disease
AU2016200697B2 (en) Predicting risk of major adverse cardiac events
AU2016200419B2 (en) Predicting mortality and detecting severe disease
AU2012202069B2 (en) Predicting mortality and detecting severe disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired